Pharma BD Deal Intelligence
Merck KGaA, Darmstadt, Germany / Mersana Therapeutics, Inc.
2022 · Co-Development · Pending
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2027 at the earliest for this deal, once/if it closes.
Key facts
- Announced Dec 22, 2022
- Deal type Co-Development
Related deals
- Merck KGaA, Darmstadt, Germany / Artios Pharma Limited (2020)
- Merck KGaA, Darmstadt, Germany / C4 Therapeutics, Inc. (2024)
- Merck KGaA, Darmstadt, Germany / Mirror Biologics, Inc. (2025)
- Merck KGaA, Darmstadt, Germany / F-star Therapeutics, Inc. (2022)
- Merck KGaA, Darmstadt, Germany / Jiangsu Hengrui Pharmaceuticals Co. Ltd. (2023)
- Merck KGaA, Darmstadt, Germany / Y-Trap, Inc. (2019)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2022 deals · Merck KGaA, Darmstadt, Germany deals